Prescription Drug Cost Statistics (2026)

US retail prescription drug spending was $467.0 billion in 2024, up 7.9% from $432.9 billion the year before.

The long arc is steeper than any single year suggests: $122.0 billion in 2000, $253.4 billion in 2010, $333.8 billion in 2019 and $467.0 billion in 2024.

Total US health spending in 2024 was $5.28 trillion, $15,474 per person and 18.0% of GDP, and it grew 7.2%. Drug spending grew slightly faster than the whole.

The CMS line covers retail prescription drugs, meaning those dispensed by a pharmacy for a patient to take away.

Drugs administered in a hospital or a physician's office are counted inside hospital care and physician services instead, not here. That includes most infused and injected treatments, which are among the most expensive drugs in use.

So $467.0 billion is a floor on what the country spends on medicines, and any claim built on it that does not say so overstates its own precision.

Of the $467.0 billion in 2024, private health insurance paid $172.1 billion, Medicare $162.8 billion, out-of-pocket spending $55.0 billion, Medicaid $53.9 billion and CHIP $3.9 billion.

Households therefore paid 11.8% of the retail drug bill directly.

That is the single most counterintuitive number in this dataset, because public attention to drug prices is not remotely proportional to the share of them that households pay at the counter.

In 2000, households paid $38.8 billion of a $122.0 billion drug bill, or 31.8%.

In 2024 they paid $55.0 billion of a $467.0 billion bill, or 11.8%.

So total spending grew by about 283% while the amount households paid directly grew by about 42%. The bill moved onto insurers and public programmes rather than disappearing.

Medicare paid $1.6 billion for retail prescription drugs in 2000 and $162.8 billion in 2024.

The Part D benefit began in 2006, and it moved a large block of spending from older households' pockets onto the programme.

That single change explains much of the fall in the out-of-pocket share, because the population that fills the most prescriptions is the one that gained coverage.

At $467.0 billion, retail prescription drugs are 8.8% of the $5.28 trillion national health bill.

For comparison, dental services were $189.2 billion and home health care $169.4 billion in the same year.

Total out-of-pocket spending across all health care was $556.6 billion, so retail drugs account for about a tenth of what households pay directly for health care of every kind.

Dividing $467.0 billion across the population gives roughly $1,370 per person a year, which describes almost nobody.

Prescription spending is extremely skewed: most people fill few or no prescriptions in a year, while a small group on specialty treatment accounts for a large share of the total.

The planning question is therefore not the average but the ceiling, which is what a plan's out-of-pocket maximum sets and what makes that figure worth knowing before you need it.

For anyone with insurance, the worst realistic drug year is bounded by the plan's annual out-of-pocket limit rather than by the price of any drug.

That converts an unbounded risk into a known one, which is exactly the shape of risk that an emergency fund can be sized against.

It is also the number that differs most between plans that look similar on premium, and it is the one worth comparing during open enrolment.

Prescription costs are recurring, predictable in kind if not in amount, and qualify as medical expenses.

An HSA is the only account that is untaxed going in, untaxed while invested and untaxed coming out for qualified medical costs, which makes it the cheapest way to pay a bill you know is coming.

The constraint is that it requires a high-deductible health plan, so the decision is a plan choice as much as an account choice.

Growth accelerated: drug spending rose 7.9% in 2024 after 10.8% in 2023, against 5.2% average growth over the previous decade.

Out-of-pocket spending has been essentially flat since 2022, at $54.3 billion, $55.5 billion and $55.0 billion.

That combination, rising total spending with flat household spending, is the clearest single statement of where the cost pressure is landing, and it is not on the pharmacy counter.

The National Health Expenditure Accounts are the official estimates of US health spending, running back to 1960, and cover goods and services, public health activity, government administration, non-medical insurance and health-related investment.

They are presented by type of service, source of funds and type of sponsor, which is what allows the who-pays split above.

Figures are calendar-year and are revised, so a number quoted for an earlier year from an older release may differ slightly from the current series.

All spending figures are from the CMS National Health Expenditure Accounts, calendar years 1960 to 2024, specifically the type-of-service and source-of-funds tables.

The $5.3 trillion total, the $15,474 per person figure, the 18.0% of GDP and the 7.2% growth rate are CMS's own headline figures for 2024.

The out-of-pocket share percentages and the per-person drug figure are our arithmetic on the CMS series, and are labelled as such rather than presented as published values.